Figure 2: Expression of CD5+CD19+ B cells in blood sample of pretreatment, posttreatment, and control groups. (a) CD5+CD19+ B cells shown by FACS. (b) CD19+ and CD5+CD19+ B cells percentage in peripheral blood lymphocytes ( , compared with Pre-T and control; , compared with Pre-T and control). (c) Comparison of peripheral blood CD5+CD19+ B cells in individual patients with thyroid papillary carcinoma before and after 131I radioablation.